Hematology/Oncology Clinics of North America 9(5): 1089-1107, 1995.
Olsen EA, Bunn PA
All of the recombinant interferons are active agents for the systemic treatment of mycosis fungoides and Sezary syndrome. The response rates are similar to those observed with systemic chemotherapy. There is no clear evidence that combining interferons with other systemic therapies increases the response rates. The combination of interferon with PUVA provides provocative results. The optimal role of interferons in the treatment of mycosis fungoides and Sezary's syndrome is undefined.
Rheinische Friedrich- Wilhelms- Universität Bonn